Senate Bill Asks for Strategy to Reduce Reliance on Chinese Pharma Inputs
A bill introduced by Sen. James Lankford, R-Okla., the text of which was published Aug. 11, would require the administration to produce a report on how to develop a more secure supply chain for pharmaceuticals and their active ingredients that has less reliance on China.
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
One of the elements Lankford wants in the report is "a description of the work of the United States Trade Representative to engage with the governments of those countries to decrease trade barriers for the development, production, refinement, and transportation of such products and ingredients."
The administration should also report to Congress on the finished drugs from China that hold more than a 20% U.S. market share and the active pharmaceutical ingredients from China that hold more than a 20% U.S. market share.
The report would be due 180 days after the enactment of the bill.